

JUN 12 2001

K010780

## 510(k) Summary

---

**Name of Sponsor:** DePuy Orthopaedics, Inc.  
700 Orthopaedic Drive  
Warsaw, Indiana 46581-0988  
Est. Reg. No. 1818910

**510(k) Contact:** Marcia J. Arentz  
Senior Regulatory Associate  
Phone: (219) 371-4944  
FAX: (219) 371-4987

**Trade Name:** Trochanteric Nail

**Common Name:** Bone fixation device

**Classification:** ~~Class II~~ Device per 21 CFR 888.3020  
Intramedullary fixation rod  
Description: Rod, Fixation, Intramedullary and  
Accessories, Metallic and Non-collapsible

**Device Product Code:** Code: 87NDE or 87HSB  
No performance standards have been established  
under Section 514 of the Federal Food, Drug,  
and Cosmetic Act for intramedullary nails.

**Substantially Equivalent Device:** Synthes Proximal Femoral Nail K973240  
ACE AIM Femoral Nail K871539

**Device Descriptions:** The Trochanteric Femoral Nail System consists  
of an intramedullary nail, lag screw, end cap, and  
optional anti-rotation screw, all manufactured  
from Titanium (Ti-6Al-4V ELI) which are used  
to treat fractures in the proximal portion of the  
femur.

000005

## **510(k) Summary (continued)**

### **Indications for use:**

The Trochanteric Nail System is intended to treat stable and unstable proximal fractures of the femur including pertrochanteric fractures, intertrochanteric fractures, high subtrochanteric fractures and combinations of these fractures.

### **Substantial equivalence:**

The Trochanteric Nail System has the same intended use, is manufactured from the same material and has the same design features as the predicate device and is therefore substantially equivalent.



JUN 1 2 2001

Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

Ms. Marcia J. Arentz  
Senior Regulatory Associate  
DePuy Orthopedics, Inc.  
700 Orthopedic Drive  
P.O. Box 988  
Warsaw, Indiana 46581-0988

Re: K010780  
Trade Name: Trochanteric Nail  
Regulation Number: 888.3020  
Regulatory Class: II  
Product Code: HSB  
Dated: March 14, 2001  
Received: March 15, 2001

Dear Ms. Arentz:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general control provisions of the Act. The general control provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the current Good Manufacturing Practice requirement, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic (QS) inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4659. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or at (301) 443-6597, or at its Internet address "<http://www.fda.gov/cdrh/dsmamain.html>".

Sincerely yours,

A handwritten signature in black ink, appearing to read "Celia M. Witten" followed by a stylized flourish.

Celia M. Witten, Ph.D., M.D.  
Director  
Division of General, Restorative and  
Neurological Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

Enclosure

510(k) Number (if known): K010780

Device Name: **Trochanteric Nail**

**Indications for Use:**

The Trochanteric Nail System is intended to treat stable and unstable proximal fractures of the femur including pertrochanteric fractures, intertrochanteric fractures, high subtrochanteric fractures and combinations of these fractures.

---

Concurrence of CDRH, Office of Device Evaluation

Prescription Use ☒   
 (Per 21 CFR 801.109)

OR Over-The-Counter Use

*D. M. Phellows for CDRH*  
(Division Sign-Off)  
Division of General, Restorative  
and Neurological Devices

510(k) Number K010780

000003